Curated News
By: NewsRamp Editorial Staff
September 24, 2025
Oncotelic's Injectable Breast Cancer Drug Gets Australian Trial Approval
TLDR
- Oncotelic Therapeutics' Sapu003 clinical trial approval gives investors early access to a potentially superior breast cancer treatment with full drug absorption advantages.
- Sapu003 uses Deciparticle technology to deliver Everolimus intravenously, achieving 100% absorption compared to oral version's 10%, with Phase 1 trial determining optimal dosing.
- This clinical trial aims to provide longer-lasting disease control and improved outcomes for breast cancer patients, advancing cancer treatment worldwide.
- Sapu Nano's injectable Everolimus transforms a 10% absorption oral drug into fully bioavailable treatment using innovative nanoparticle delivery technology.
Impact - Why it Matters
This development matters because breast cancer remains one of the most prevalent cancers worldwide, affecting millions of patients who often face limited treatment options and significant side effects from current therapies. The innovation of converting an established oral cancer drug into an injectable form with potentially 90% better absorption could dramatically improve treatment outcomes and quality of life for patients. Current oral Everolimus (Afinitor) is used in various cancer treatments but its low absorption rate limits effectiveness and requires higher doses that increase side effects. If successful, this intravenous delivery approach could set a new standard for how existing cancer drugs are reformulated, potentially extending to other medications beyond breast cancer treatment. For the pharmaceutical industry, this represents an important advancement in drug delivery technology that could breathe new life into established therapeutics, offering improved efficacy without the lengthy development process of entirely new drugs.
Summary
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company, has announced a significant breakthrough through its joint venture GMP Biotechnology Limited. The company's Sapu Nano division has received approval from Australia's Human Research Ethics Committee to begin patient enrollment in a Phase 1 clinical trial for Sapu003, an injectable form of Everolimus specifically targeting breast cancer treatment. This development represents a major advancement in oncology therapeutics, as Everolimus, currently marketed as Afinitor(R) in oral form, suffers from limited absorption rates of only about 10% when taken orally. The innovative approach utilizes Sapu Nano's proprietary Deciparticle(TM) technology to deliver the drug intravenously, potentially allowing for full drug absorption into the bloodstream and improved therapeutic efficacy.
The clinical trial will focus on determining optimal dosing parameters for future studies, including potential Phase 3 trials, with the ultimate goal of providing longer-lasting disease control and improved outcomes for breast cancer patients. Preclinical data already suggests this intravenous delivery method could significantly enhance efficacy compared to the oral version. Oncotelic Therapeutics, led by CEO Dr. Vuong Trieu, who holds 39 issued U.S. patents and has filed over 150 patent applications, maintains a 45% ownership stake in GMP Bio through this joint venture arrangement. The company's strategic position in oncology and rare disease therapeutics is further strengthened by this development, which complements its existing pipeline of innovative drug candidates addressing high-unmet-need cancers and rare pediatric indications.
This announcement was distributed through InvestorWire, which is part of the Dynamic Brand Portfolio at IBN, providing specialized communications services including wire-grade press release syndication and enhanced distribution to thousands of outlets and social media platforms. The news highlights Oncotelic's commitment to advancing cancer treatment options through innovative delivery technologies that could revolutionize how established drugs are administered and absorbed by patients. The successful development of Sapu003 could represent a paradigm shift in breast cancer treatment, potentially offering new hope for patients who have limited options with current oral formulations of established cancer medications.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's Injectable Breast Cancer Drug Gets Australian Trial Approval
